Klemazice

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klemazice

What is Klemazice?

Klemazice is a pharmaceutical medication classified as an antihistamine. It is primarily utilized to manage symptoms associated with allergic reactions and various upper respiratory conditions. By targeting specific physiological pathways, the medication helps reduce the body's natural response to environmental triggers.

Mechanism of Action

The active component in Klemazice functions as an H1-receptor antagonist. In the body, certain cells release a substance called histamine when they encounter allergens like pollen, pet dander, or dust. Histamine binds to H1 receptors, leading to common allergy symptoms such as swelling, itching, and increased mucus production. Klemazice works by competitively blocking these receptors, thereby preventing histamine from exerting its effects on the tissues.

Therapeutic Applications

Klemazice is commonly used to provide relief from a variety of symptoms, including:

  • Allergic Rhinitis: Easing sneezing, runny nose, and itchy or watery eyes caused by seasonal or perennial allergies.
  • Urticaria: Managing the discomfort associated with hives and other allergic skin reactions characterized by itching and redness.
  • Common Cold Symptoms: Addressing minor respiratory distress and nasal congestion when associated with allergic sensitivities.

Pharmacological Profile

As a first-generation antihistamine, Klemazice is known for its ability to cross the blood-brain barrier. This characteristic distinguishes it from newer, second-generation antihistamines. Due to its interaction with the central nervous system, it may influence wakefulness and other neurological functions while performing its primary anti-allergic role. The medication is typically absorbed through the gastrointestinal tract and metabolized by the liver before being eliminated from the system.

What side effects are possible with Klemazice?

The possible side effects and safety characteristics of Klemazice (Esomeprazol) are documented in official regulatory classifications by frequency and affected organ system.

Adverse Reactions by Classification

Adverse reactions classified as Common (occurring in 1% to 10% of patients) primarily affect the Gastrointestinal and Nervous Systems, including headache, diarrhea, abdominal pain, flatulence, and nausea. Reactions classified as Uncommon include insomnia, dizziness, and dermatitis.

Serious Adverse Reactions (SARs), which are documented as Rare or Very Rare, include severe hypersensitivity events, Acute Interstitial Nephritis (AIN), and severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS). Effects on the blood system, such as agranulocytosis, are also documented as very rare.

Exposure-Related Safety Patterns

The regulatory safety profile notes that certain risks are associated with long-term daily use. This includes an increased risk of bone fracture of the hip, wrist, or spine with prolonged use (typically ge 1 year). Additionally, Hypomagnesemia (low blood magnesium levels) has been reported rarely with prolonged treatment, and Vitamin B-12 deficiency is cited with daily long-term use (e.g., ge 3 years). Fundic gland polyps (benign) have also been reported with prolonged use.

Safety Constraints and Considerations

The official label states that a symptomatic response to treatment does not exclude the presence of gastric malignancy. Furthermore, the medicine may interfere with certain diagnostic investigations for neuroendocrine tumors by increasing chromogranin A (CgA) levels. Safety statements also address use in patients with severe hepatic impairment and list specific common adverse reactions for pediatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Klemazice (Esomeprazole) defines overdosage based on available clinical data, where manifestations are typically variable and often resemble common adverse reactions. In cases of over-exposure, immediate medical attention must be sought.

Documented Manifestations and Management

Official documents indicate that signs of over-exposure may affect multiple physiological systems. Documented manifestations have included central nervous system effects such as confusion, drowsiness, and headache. Tachycardia (rapid heartbeat) has also been reported, alongside gastrointestinal symptoms like nausea and dry mouth.

Regulators mandate that the standard procedure for managing overdosage is strictly symptomatic and supportive treatment. A critical constraint noted in official labeling is that no specific antidote for Esomeprazole is known. Furthermore, due to the drug’s extensive protein binding, it is not expected to be removed by dialysis as an effective management measure. Treatment focuses entirely on supporting the patient's vital functions and managing the specific symptoms that are present following over-exposure. Clinical experience with doses far exceeding the usual recommended maximum is limited.

Therapeutic Uses of Klemazice

What Klemazice Treats: Main Uses and Benefits

Klemazice is commonly used across conditions presenting with acute episodes involving excess stomach acid. This medication is primarily applied in addressing symptom clusters that create noticeable physiological strain on the upper digestive system. Its therapeutic domains are relevant when supportive symptom management is appropriate for conditions such as Gastroesophageal Reflux Disease (GERD), the management of ulcers associated with H. pylori infection, ulcers related to NSAID use, and pathological hypersecretory conditions like Zollinger-Ellison syndrome.

The medication is used in clinical settings that involve acute or unstable symptom patterns where assistance with discomfort is needed. Klemazice provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods. “It is commonly used to help with managing symptoms related to inflammatory or irritative states in the upper gastrointestinal tract.” This helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Supports comfort during periods of heightened physiological activity

Eligibility and Restrictions for Use

Klemazice eligibility is defined by absolute prohibitions and specific population restrictions documented in official regulatory labeling.

Contraindicated Populations

Patients must not use Klemazice if they have a known hypersensitivity to the active ingredient Esomeprazol, any substituted benzimidazole, or any formulation component. Use is also contraindicated if a patient is receiving concomitant treatment with the antiretroviral drug Nelfinavir. The medicine is prohibited for patients with rare hereditary problems of fructose intolerance due to excipients.


Age-Related Eligibility and Restrictions

Age Group Eligibility Status (Official Labeling)
Adults, Adolescents (12+ years) Approved for standard labeled use.
Children (1 year to 11 years) Approved for specific conditions like symptomatic GERD.
Infants (1 month to < 1 year) Use established for short-term treatment of Erosive Esophagitis.
Infants (< 1 month) Safety and effectiveness have not been established.

Conditional Use and Special Populations

For patients with severe hepatic impairment (Child-Pugh Class C), use is restricted to an officially defined maximum daily dose. Patients with severe renal insufficiency should be treated with caution due to limited clinical experience. Regulatory information advises that Klemazice should be used with caution during pregnancy and is generally not recommended while breastfeeding due to insufficient data.

What should I know about interactions with other medicines?

Klemazice, a proton pump inhibitor, can interact with other products primarily through two mechanisms: significantly decreasing stomach acid and inhibiting the CYP2C19 liver enzyme.

Impact on Other Medicines

Mechanism Interacting Product/Class Interaction Context/Restriction
Decreased Stomach Acid Antifungals (e.g., ketoconazole, itraconazole), Antivirals (e.g., atazanavir, rilpivirine), Iron salts Absorption may be reduced or bioavailability decreased; avoid use with rilpivirine-containing products.
Decreased Stomach Acid Digoxin Absorption may be increased, necessitating monitoring for potential toxicity.
CYP2C19 Inhibition Clopidogrel Avoid concomitant use as Klemazice may decrease the formation of clopidogrel’s active metabolite, reducing its effectiveness.
CYP2C19 Inhibition Cilostazol, Diazepam, Phenytoin Concentrations may be increased, requiring dose monitoring or adjustment.
Other Methotrexate (especially high-dose), Tacrolimus Serum levels may be elevated, requiring close monitoring and possible temporary Klemazice withdrawal.
Enzyme Induction St. John's Wort, Rifampin Avoid concomitant use as these inducers may reduce Klemazice plasma levels, decreasing its effect.

Other Interactions

Klemazice can increase Chromogranin A (CgA) levels, which interferes with diagnostic testing for neuroendocrine tumors; the product should be temporarily discontinued at least 14 days prior to CgA assessment.

Mechanism of Action

Klemazice (Esomeprazole) acts as a specific, irreversible inhibitor of the H^+/ K^+-ATPase enzyme, commonly known as the Proton Pump, which is the final component in the gastric acid secretion pathway. This action involves the drug’s active metabolite forming a covalent bond with specific cysteine residues on the enzyme, functionally blocking the exchange of hydrogen ( H^+) ions necessary for producing hydrochloric acid ( HCl). The drug is a prodrug that must undergo an acid-catalyzed conversion in the highly acidic environment of the parietal cell canaliculi to become active, which focuses the inhibitory effect at the required cellular site. Because the inhibition is permanent, the resulting functional suppression of gastric acid output is sustained, lasting until the stomach cells synthesize new Proton Pumps, which results in the elevation of the intragastric pH over a 24-hour cycle.

Dosage and Administration Information

Administration and Dosing Guidelines

The administration of Klemazice follows specific dosing and procedural rules. This drug is administered via the Oral route (as delayed-release capsules or suspension) or the Intravenous (IV) route (as an injection or infusion).

Dosing and Timing

Administration Scope Requirement (Adults)
Route Oral or Intravenous (IV)
Standard Oral Frequency Once Daily (QD) (20 mg or 40 mg)
Special Oral Frequency Twice Daily (BID) (e.g., 40 mg for pathological hypersecretory conditions)
Timing in Relation to Meals Oral doses must be taken at least one hour before meals.

Preparation and Special Conditions

Oral Administration: Delayed-release capsules must be swallowed whole and should not be crushed or chewed. For patients with difficulty swallowing, the capsule contents may be opened and sprinkled over a spoonful of applesauce and swallowed immediately; the pellets must not be chewed. The medication is also available as a powder for delayed-release oral suspension.

IV Administration: Intravenous powder requires reconstitution and, for infusion, further dilution with approved solutions (e.g., 0.9% Sodium Chloride Injection, USP). The IV line must be flushed before and after administration with an approved solution, and no other medications should be co-administered via the same line.

Missed Dose: If a Once Daily dose is missed, take it as soon as remembered, unless it is less than 12 hours before the next scheduled dose. If a Twice Daily dose is missed, take it as soon as remembered, unless it is less than 4 hours before the next dose. Do not take a double dose to compensate for the missed one.

Age and Hepatic Rules: Pediatric dosing is weight- and age-specific. For adult patients with severe liver impairment, the maximum recommended daily oral dose must not exceed 20 mg.

Recent Clinical Evidence

Research evidence / Overview of studies for Klemazice


Evidence for Use in Acid Reflux and Esophageal Healing

Research exploring Klemazice in the context of acid reflux focuses primarily on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies evaluated the medicine in the context of severe acid reflux (Erosive Esophagitis) and symptomatic relief. Outcomes examined included endoscopic measures that assess the status of the esophageal lining (healing or damage) and outcomes related to physical discomfort like heartburn. Findings describe patterns observed in the evolution of symptoms over four to eight weeks. However, controlled trial data for observing patients over periods exceeding six months is limited, and long-term outcomes are not fully established.


Evidence for Use in Ulcer Management and H. pylori Eradication

Klemazice was studied for its inclusion in studies concerning stomach and duodenal ulcers and in regimens intended to eradicate the H. pylori bacteria. These studies usually explored the medicine as one part of a combination regimen (triple therapy). Researchers monitored the success rates of the H. pylori status and the occurrence of new stomach ulcers in at-risk patients taking continuous NSAIDs. The evidence structure relies on its use within a multi-drug regimen, and data show patterns related to monitored eradication status varying based on local antibiotic resistance rates.


Evidence for Rare Conditions and Key Uncertainties

Research has explored Klemazice in the context of rare conditions characterized by severe, excessive stomach acid production, such as Zollinger-Ellison syndrome (ZES). Due to the low prevalence of ZES, studies are typically open-label and non-randomized, restricting the ability to conduct large comparative trials. Similarly, while research examined Klemazice in infants and children, data for certain pediatric groups remain insufficient. A primary area of uncertainty across all indications involves the clinical importance of statistical differences versus other similar medications, where findings may exist but the practical significance is often debated in the literature.

Key Studies & References

  1. Efficacy and safety of esomeprazole for the treatment of gastroesophageal reflux disease in children: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Klemazice (FAQ)

Q: How quickly does Klemazice start working after you take it?

A: Studies and official product information indicate that the drug begins working soon after the first dose, with the highest concentration in the blood occurring within a couple of hours. However, for full relief of frequent heartburn, the over-the-counter (OTC) label advises that it may take 1 to 4 days of continued use to feel the full therapeutic effect.

Q: Can Klemazice cause extreme fatigue or drowsiness?

A: Regulatory documents list drowsiness (somnolence) and fatigue as possible effects, though they are not commonly reported side effects in most clinical trials. If unexpected or extreme tiredness is experienced, a healthcare provider should be consulted.

Q: Are there any common foods or drinks that interact badly with Klemazice?

A: The official regulatory guidance requires that the oral dose of Klemazice must be taken at least one hour before a meal for best absorption. However, outside of the required timing with meals, the product label does not typically list specific, serious interactions with common foods or non-alcoholic beverages.

Q: Is it safe to take Klemazice every day for a long time?

A: The drug is approved for short courses for most conditions, such as 4 to 8 weeks, with some maintenance use up to 6 months. Official product information includes specific warnings about risks associated with long-term daily use (for example, one year or longer), such as an increased risk of bone fracture or deficiencies in Vitamin B-12 or magnesium. Because of these documented risks, the need for long-term use should be carefully monitored by a healthcare professional.

Q: Does Klemazice have a risk of addiction or dependence?

A: Klemazice is not a controlled substance and does not carry a reported risk of addiction or drug abuse. However, some users may experience a temporary return of acid symptoms (rebound acid hypersecretion) when stopping the medication, which has been noted in the literature.

Q: How long do most people need to take Klemazice for a full course of treatment?

A: Studies and official information indicate that the standard treatment duration for conditions like healing erosive esophagitis is typically 4 to 8 weeks. Shorter courses are often used for symptomatic relief, while maintenance therapy, when indicated, has been studied for periods up to 6 months.

Q: Is it normal to feel a bit dizzy when first starting Klemazice?

A: Dizziness is a documented, though uncommon, side effect, meaning it occurs in less than 1% of patients. While it is a possible adverse reaction, feeling dizzy is not considered a universally normal or expected experience when starting the medication.

Q: Are there generic versions of Klemazice available yet?

A: Yes, regulatory records, such as the FDA's Orange Book, confirm that the FDA has approved generic versions of Klemazice (esomeprazole). These are generally available in the same strengths as the brand-name product.

Q: Is Klemazice safe for use during pregnancy or breastfeeding?

A: Official information indicates that the drug should be used during pregnancy only after a healthcare provider has determined that the potential benefit justifies the potential risk, particularly since data on developmental outcomes is limited. It is not recommended while breastfeeding because data on how much of the drug passes into breast milk are lacking.

Q: Will alcohol increase the side effects of Klemazice?

A: The official product label does not list a specific interaction between Klemazice and alcohol. While the product label does not list a specific drug interaction with alcohol, any questions about alcohol consumption while taking medication are best directed to a healthcare provider.

Q: How long does Klemazice stay in your system after stopping treatment?

A: Regulatory data on the drug's metabolism show it has a short half-life, meaning the drug substance is quickly eliminated from the bloodstream (within a few hours). However, the therapeutic effect of suppressing acid production lasts much longer, usually up to 24 hours, because the drug permanently blocks the acid-producing pumps until new ones are made.

Q: Does Klemazice require special monitoring, like blood tests, while taking it?

A: Special monitoring may be necessary, particularly with long-term use, including monitoring blood levels of magnesium to check for hypomagnesemia (low magnesium). Because the drug can interfere with certain diagnostic blood tests (e.g., Chromogranin A or CgA), a healthcare provider will typically advise temporarily stopping the medicine before such tests are performed.

Q: Can men and women use Klemazice with the same effect?

A: Clinical studies typically include both male and female patients, and the drug is generally approved and dosed without specific adjustments based on gender. Official product information does not indicate any known difference in its effectiveness between men and women.

Q: Are there any natural remedies that should be avoided when taking Klemazice?

A: Official labeling specifically advises against the concomitant use of Klemazice with St. John's Wort, a natural remedy, because it may significantly reduce the drug's effectiveness. Consultation with a healthcare provider is recommended before combining Klemazice with any other natural or herbal remedies.

Q: What's the typical time frame for seeing the full benefits of Klemazice?

A: According to clinical studies, the full benefits for healing conditions like erosive esophagitis were generally achieved within 4 to 8 weeks of continuous use. For relief of daily symptoms, the full beneficial effect usually occurs within a few days of starting treatment.

Q: Does Klemazice cause changes in mood or anxiety?

A: Changes in mood or anxiety are not listed among the common side effects. However, rare psychiatric events, such as agitation, confusion, or depression, have been reported in post-marketing experience with this drug class.

Q: Does taking Klemazice make you more sensitive to sunlight?

A: The product label lists general skin reactions, but it does not specifically list photosensitivity (sun sensitivity) as a common side effect. However, there has been rare post-marketing reporting of conditions sensitive to sun exposure, such as cutaneous lupus erythematosus (CLE).

Q: Is Klemazice considered a Schedule IV controlled substance?

A: No. Official government listings, such as those from the Drug Enforcement Administration (DEA), confirm that Klemazice (esomeprazole) is not classified as a controlled substance.

Q: How does Klemazice affect the liver?

A: The liver is the primary organ that breaks down Klemazice. Official regulatory information indicates that for patients with severe liver impairment, the maximum recommended daily dose must be restricted. This indicates that dosage adjustments or careful consideration by a healthcare professional may be needed when liver function is significantly compromised.

Q: Can older adults (seniors) take Klemazice safely?

A: According to the geriatric use section of the label, no overall differences in safety or effectiveness have been observed between older adults and younger patients. Official information notes that due to the greater likelihood of reduced organ function in older adults, monitoring by a healthcare provider may be appropriate.

Q: What's the difference between the immediate-release and extended-release forms of Klemazice?

A: Klemazice is primarily formulated as delayed-release capsules, tablets, or suspensions. This delayed-release design is essential to protect the drug from stomach acid until it reaches the small intestine. The FDA label does not typically feature standard immediate-release or extended-release forms.

Q: Is it possible to be allergic to Klemazice?

A: Yes, official regulatory documents state that the drug is contraindicated (must not be used) in anyone with a known hypersensitivity or allergy to the active ingredient, Esomeprazole, or related chemical classes. Allergic reactions, including severe ones, have been reported in post-marketing experience.

Q: Does taking Klemazice cause dry mouth or dry eyes?

A: Dry mouth is a documented side effect reported in post-marketing experience and is occasionally listed as a common adverse reaction. Dry eyes are not typically listed in the official product information.

Q: Can someone with a history of heart issues take Klemazice?

A: Heart issues are not listed as a contraindication in the product label. However, the medicine has been associated with rare reports of hypomagnesemia (low magnesium), which can lead to serious adverse cardiac events. For patients with pre-existing heart issues, consultation with a healthcare provider is important to determine if closer monitoring is necessary.

Q: Is it okay to take vitamins or supplements while on Klemazice?

A: Official information indicates that long-term use (typically three years or more) may lead to a Vitamin B-12 deficiency, suggesting supplementation may be needed. Conversely, certain supplements, such as St. John’s Wort, are listed as potential drug interactions and their use in combination with Klemazice is advised against.

How should Klemazice be stored and disposed of?

How to Store and Dispose of Klemazice?

Klemazice must be stored according to official regulatory specifications to maintain its effectiveness and stability. The medicine requires storage at Controlled Room Temperature (CRT), typically mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F), and must be stored below mathbf30 C.

It is mandatory to protect the product from moisture and light and keep it in its tightly closed, original container. Do not refrigerate or freeze the oral forms. All medication must be kept out of the sight and reach of children.

Unused or expired product should not be disposed of via household wastewater or the sanitary sewer system. Disposal must adhere to local and national pharmaceutical waste handling regulations, utilizing official take-back programs or designated collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klemazice found in:

A-Z Index: